Skip to content

Price / sales at other companies

AbbVie logo
AbbVieABBV
6.1×-0.3×
Bausch + Lomb logo
Bausch + LombBLCO
1.1×0.0×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
35.4×+15.9×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Warby Parker logo
Warby ParkerWRBY
2.9×+0.1×
Glaukos logo
GlaukosGKOS
11.3×-2.4×

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s price / sales?
Tarsus Pharmaceuticals, Inc. (TARS) reported price / sales of 5.6× in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s price / sales changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s price / sales decreased by 38.4% year-over-year, from 9.1× to 5.6×.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s price / sales?
Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s price / sales has grown at a -1.4% compound annual growth rate (CAGR), from 8.1× to 7.7×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.